MB2607 COBALT BLUE ROTOMOLD NP STAN-TONE VC-20326 BLUE FTMB (1% 9605 Yellow) FDA 950

To help customers manage their risk potential, dedicated facilities and systems govern the production of our medical colorants and performance masterbatches. Our ‘open to audit’ policy and controlled operations help meet FDA and other regulatory guidelines regarding fully traceable production.

By helping to maintain the freshness of food in packaging and limiting the growth of bacteria and fungi, it’s possible to reduce food waste and improve food hygiene,” said Say-Eng Lee, vice president and general manager, Color & Additives Asia. It is also compliant with US FDA and EU regulations.

To help customers manage their risk potential, dedicated facilities and systems govern the production of our medical colorants and performance masterbatches. Our ‘open to audit’ policy and controlled operations help meet FDA and other regulatory guidelines regarding fully traceable production.

Slide 1 PolyOne Corporation Page 1 PolyOne Investor Presentation Goldman Sachs 2015 US Emerging/ SMID Cap Growth Conference November 2015 PolyOne Corporation Page 2 Forward-Looking Statements  In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Platform operating income mix percentage 2005* 2008* 2010* 2013 2014 2015 YTD Global Color, Additives and Inks $ 4.3 $ 28.1 $ 37.7 $104.0 $124.9 $ 107.9 Global Specialty Engineered Materials 0.4 17.6 49.7 57.2 72.4 63.2 Designed Structures and Solutions - - - 33.4 45.1 12.0 Specialty Platform $ 4.7 $ 45.7 $ 87.4 $194.6 $242.4 $ 183.1 Performance Products and Solutions 75.7 31.3 54.0 56.0 63.1 43.9 Distribution 19.5 28.1 42.0 63.3 68.2 52.4 Joint ventures 91.9 28.6 18.9 - - — Corporate and eliminations (51.5) (425.1) (27.7) (82.4) (218.6) (59.8) Operating income (loss) GAAP $140.3 $(291.4) $174.6 $231.5 $155.1 $ 219.6 Less: Corporate operating expense 51.5 425.1 27.7 82.4 218.6 59.8 Operating income excluding Corporate $191.8 $133.7 $202.3 $313.9 $373.7 $ 279.4 Specialty platform operating mix percentage 2% 34% 43% 62% 65% 66% Adjusted EPS is calculated as follows: Adjusted EPS 2006Y* 2007Y* 2008Y* 2009Y* 2010Y 2011Y 2012Y 2013Y 2014Y Net income attributable to PolyOne common shareholders $ 130.9 $ 40.9 $ (417.0) $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 Joint venture equity earnings, after tax (68.5) (26.1) (20.8) (19.0) (14.7) (3.7) - - - Special items, after tax(1) (21.2) 41.4 310.0 (31.0) 15.8 (30.5) 35.7 30.4 101.0 Tax adjustments(2) (30.0) (30.7) 147.2 (44.9) (88.3) (42.3) 0.5 2.2 (10.5) Adjusted net income $ 11.2 $ 25.5 $ 19.4 $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 Diluted shares 92.8 93.1 92.7 93.4 96.0 94.3 89.8 96.5 93.5 Adjusted EPS $ 0.12 $ 0.27 $ 0.21 $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 2 Adjusted EPS 2011 Q3 2012 Q3 2013 Q3 2014 Q3 2015 Q3 Net income attributable to PolyOne common shareholders $ 16.0 $ 19.4 $ 23.2 $ 32.3 $ 44.5 Special items, after tax(1) 3.1 5.3 10.5 13.2 12.6 Tax adjustments(2) (0.3) 0.1 1.8 (0.1) (9.6) Adjusted net income $ 18.8 $ 24.8 $ 35.5 $ 45.4 $ 47.5 Diluted shares 94.3 90.2 98.1 93.1 88.4 Adjusted EPS $ 0.20 $ 0.27 $ 0.36 $ 0.49 $ 0.54 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principal or discontinued operations. (1) Special items are a non-GAAP financial measure and are used to determine adjusted earnings. Appendix Q3 2015 Financial Highlights At a Glance�Global Color, Additives and Inks At a Glance�Global Specialty Engineered Materials At a Glance�Designed Structures and Solutions At a Glance�Performance Products and Solutions At a Glance�Distribution Plastics: Key to Future Sustainable Development Commitment to Operational Excellence Application Examples Outdoor Applications Slide Number 27 Authentication Technology 2015 Range Rover Evoque Interior Slide Number 30 Metal Replacement Solutions High-Barrier Packaging Containers Aerospace Applications Baird Non GAAP Rec.pdf Baird - November 10, 2015

MEVOPUR Amber for PET Pharma Pkg Application Bulletin_CN5.12-1 * 可根据要求提供 FDA/EU合规信息 应用公告 Mevopur™应用于药品包装的 医疗级琥珀色系着色剂和配方 埃万特时刻关注着医疗保健行业法规的演变，并 提前在这些法规生效之前开发合规产品。 主要特性 在四个通过ISO 13485认证的医疗生产线生 产，拥有全球统一的配方，提供一致性和供 应链保障 变更控制记录的不限于CAS编号级别，降低变 更风险 不含动物源性物质和邻苯二甲酸盐 不同的琥珀色色调，可根据要求定制—偏红色 或偏黄色，和/或颜色浅或深 适用于液体形式 • • • • • 法规支持 经过预测试的原材料： - ISO 10993-1和USP第、 部分（VI级） - 欧洲药典，，美国药典， 元素分析符合ICH Q3D - USP 溶液性状、颜色标准 FDA发布的注册药品主文件（III类） 食品接触符合FDA/EU*要求 符合YBB00102002-2015 (口服液体药用聚酯 瓶）标准 • • • • 1.844.4AVIENT www.avient.com 适用医疗保健使用限制—见下文。

PEACH FDA PFIZER DEJA BLUE BLUE PEARL

7AY621407MB YELLOW FDA BLUE TINT BLUE 295C

FDA BLUE BLUE BLUE

VIRTUAL BLUE D2086A ENDO BLUE FDA 4%BA BLUE